Symptom burden of atopic dermatitis in early childhood assessed from daily monitoring of symptoms and topical steroid use
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Symptom burden of atopic dermatitis in early childhood assessed from daily monitoring of symptoms and topical steroid use. / Ruge, Iben Frier; Thorsteinsdóttir, Sunna; Nørgaard, Sarah; Chawes, Bo L; Bønnelykke, Klaus; Stokholm, Jakob; Bisgaard, Hans.
I: Journal of the American Academy of Dermatology, Bind 84, Nr. 3, 2021, s. 725-734.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Symptom burden of atopic dermatitis in early childhood assessed from daily monitoring of symptoms and topical steroid use
AU - Ruge, Iben Frier
AU - Thorsteinsdóttir, Sunna
AU - Nørgaard, Sarah
AU - Chawes, Bo L
AU - Bønnelykke, Klaus
AU - Stokholm, Jakob
AU - Bisgaard, Hans
N1 - Copyright © 2020 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.
PY - 2021
Y1 - 2021
N2 - BACKGROUND: To our knowledge, disease burden of atopic dermatitis (AD) as number of days with symptoms and medical treatment has never been studied as measure of severity.OBJECTIVES: To investigate risk factors for AD burden in the first 3 years of life.METHODS: The Copenhagen Prospective Studies on Asthma in Childhood2010 included 700 children. AD burden was assessed by daily diary entries with information on AD and steroid days measuring 18 possible heritable, prenatal, and postnatal environmental exposures.RESULTS: The children with AD had a median (interquartile range) of 136 symptom days (61-294 days) and 72 steroid days (27-145 days) during the first 3 years of life, with the highest disease burden in the second year of life. The multivariable risk factor analysis showed that maternal AD and childhood allergic sensitization were associated with a higher number of AD days and maternal AD, filaggrin mutation, and allergic sensitization were associated with a higher number of steroid days.LIMITATIONS: Participants with a personal interest in atopic diseases could be more likely to participate.CONCLUSION: Children's burden of AD, assessed quantitatively as AD and steroid days, demonstrated positive associations with maternal AD, filaggrin mutation, and early-life allergic sensitization, with the highest disease burden in the second year of life.
AB - BACKGROUND: To our knowledge, disease burden of atopic dermatitis (AD) as number of days with symptoms and medical treatment has never been studied as measure of severity.OBJECTIVES: To investigate risk factors for AD burden in the first 3 years of life.METHODS: The Copenhagen Prospective Studies on Asthma in Childhood2010 included 700 children. AD burden was assessed by daily diary entries with information on AD and steroid days measuring 18 possible heritable, prenatal, and postnatal environmental exposures.RESULTS: The children with AD had a median (interquartile range) of 136 symptom days (61-294 days) and 72 steroid days (27-145 days) during the first 3 years of life, with the highest disease burden in the second year of life. The multivariable risk factor analysis showed that maternal AD and childhood allergic sensitization were associated with a higher number of AD days and maternal AD, filaggrin mutation, and allergic sensitization were associated with a higher number of steroid days.LIMITATIONS: Participants with a personal interest in atopic diseases could be more likely to participate.CONCLUSION: Children's burden of AD, assessed quantitatively as AD and steroid days, demonstrated positive associations with maternal AD, filaggrin mutation, and early-life allergic sensitization, with the highest disease burden in the second year of life.
U2 - 10.1016/j.jaad.2020.09.038
DO - 10.1016/j.jaad.2020.09.038
M3 - Journal article
C2 - 32950548
VL - 84
SP - 725
EP - 734
JO - American Academy of Dermatology. Journal
JF - American Academy of Dermatology. Journal
SN - 0190-9622
IS - 3
ER -
ID: 259829699